Figures & data
Table 1. Patient characteristics (N = 30).
Supplemental material
Acta Oncologica
Volume 58, 2019 - Issue 7
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy
Source:
Elsevier BV
Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy
Source:
American Society of Clinical Oncology (ASCO)
Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma
Source:
Ovid Technologies (Wolters Kluwer Health)
Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer
Source:
American Society of Clinical Oncology (ASCO)
Adjuvant Proton Beam Therapy in the Management of Thymoma: A Dosimetric Comparison and Acute Toxicities
Source:
Elsevier BV
Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment
Source:
Elsevier BV
Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy
Source:
Elsevier BV
Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma
Source:
Elsevier BV
Dose escalation in lung cancer: have we gone full circle?
Source:
Elsevier BV
Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee
Source:
Elsevier BV
Proton therapy in stage II–IV non-small cell lung cancer: pattern of care and impact on trial accrual
Source:
Informa UK Limited
Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen
Source:
Dove Medical Press Ltd.
Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction
Source:
Elsevier BV
The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma
Source:
Elsevier BV
Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non–Small Cell Lung Cancer
Source:
Elsevier BV
Adjuvant radiotherapy for completely resected stage 2 thymoma
Source:
Wiley-Blackwell
Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma
Source:
American Society of Clinical Oncology (ASCO)
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Source:
New England Journal of Medicine (NEJM/MMS)
Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies
Source:
Informa UK Limited
Postoperative Proton Therapy in the Management of Stage III Thymoma
Source:
Elsevier BV
Linking provided by
